|NASDAQ: EVAX||- / - / -|
|1.13||+0.0550||+5.12%||Vol 61.37K||1Y Perf -64.52%|
|Mar 31st, 2023 16:00 DELAYED|
|- -||0.01 0.88%|
|Target Price||13.00||Analyst Rating||Strong Buy 1.00|
|Potential %||1.05K||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-/-/-||Value Ranking||— -|
|Insiders Value % 3/6/12 mo.||-/-/-||Growth Ranking||— -|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-||Income Ranking||— -|
|Price Range Ratio 52W %||8.08||Earnings Rating||—|
|Market Cap||29.86M||Earnings Date||4th Apr 2023|
Today's Price Range
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Valuation||Value||Industry||S&P 500||US Markets|
|Financial Strength||Value||Industry||S&P 500||US Markets|
|Profitability||Value||Industry||S&P 500||US Markets|
|Revenue||Value||Industry||S&P 500||US Markets|
|Dividends||Value||Industry||S&P 500||US Markets|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||4th Apr 2023|
|Estimated EPS Next Report||-0.28|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||66.91K|
|Avg. Monthly Volume||113.28K|
|Avg. Quarterly Volume||597.23K|
Evaxion Biotech A/S (NASDAQ: EVAX) stock closed at 1.13 per share at the end of the most recent trading day (a 5.12% change compared to the prior day closing price) with a volume of 61.37K shares and market capitalization of 29.86M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the industry, sector and employs 0 people. Evaxion Biotech A/S CEO is .
The one-year performance of Evaxion Biotech A/S stock is -64.52%, while year-to-date (YTD) performance is -36.34%. EVAX stock has a five-year performance of %. Its 52-week range is between 0.92 and 3.5199, which gives EVAX stock a 52-week price range ratio of 8.08%
Evaxion Biotech A/S currently has a PE ratio of -1.50, a price-to-book (PB) ratio of 3.81, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -95.68%, a ROC of -168.27% and a ROE of 100.46%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Evaxion Biotech A/S, there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.28 for the next earnings report. Evaxion Biotech A/S’s next earnings report date is 04th Apr 2023.
The consensus rating of Wall Street analysts for Evaxion Biotech A/S is Strong Buy (1), with a target price of $13, which is +1 050.44% compared to the current price. The earnings rating for Evaxion Biotech A/S stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Evaxion Biotech A/S has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Evaxion Biotech A/S has a Neutral technical analysis rating based on Technical Indicators (ADX : 42.44, ATR14 : 0.13, CCI20 : 2.31, Chaikin Money Flow : -0.07, MACD : -0.08, Money Flow Index : 57.29, ROC : 4.63, RSI : 43.83, STOCH (14,3) : 46.67, STOCH RSI : 0.61, UO : 55.58, Williams %R : -53.33), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Evaxion Biotech A/S in the last 12-months were:
|Analyst Ratings||Current||1 M ago||3 M ago|
|Summary Rating||Strong Buy||Strong Buy||Strong Buy|
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.